Furthermore, treatment with the mineralocorticoid receptor antagonist spironolactone reduces both ROS and ox-CaMKII levels in cultured neonatal myocytes stimulated with aldosterone, thus confirming CaMKII activity contribution to aldosterone-induced mortality during myocardial infarction [129]. Here, CAMK2G is linked to myocardial infarction.